English

Immune Design Corp.

EDGAR

IMDZ Annual report amendment (10-K/A) · filed 2019-03-28

51 filing records in this dataset, filed from 2014-06-23 to 2019-03-28. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

476 thousand USD

2018 Q4 · USD

Exact inputs and evidence

Revenue: 476000 USD Source

Operating margin

-2,985.08%

2018 Q4 · %

Exact inputs and evidence

Operating Income: -57050000 USD Source
Operating Income: -42841000 USD Source
Revenue: 476000 USD Source

Operating cash flow

-11.4 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -51666000 USD Source
Operating Cash Flow: -40268000 USD Source

Free cash flow

-11.5 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -51666000 USD Source
Operating Cash Flow: -40268000 USD Source
Capital Expenditure: 390000 USD Source
Capital Expenditure: 269000 USD Source

Cash and cash equivalents: 77.9 million USD 2018-12-31 Source
Exact value

77941000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 48.2 million shares 2018-12-31 Source
Exact value

48210520 shares

Reported share-count change

0.30% · 142 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

48068650 shares · 2017-12-31· Source
48210520 shares · 2018-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

2.2 million USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Revenue: 503000 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 755000 USD · 2018-04-01 – 2018-06-30 Source
Revenue: 462000 USD · 2018-07-01 – 2018-09-30 Source
Revenue: 476000 USD · 2018-10-01 – 2018-12-31 Source

Net income

-54.8 million USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Net income: -13300000 USD · 2018-01-01 – 2018-03-31 Source
Net income: -27108000 USD · 2018-01-01 – 2018-06-30 Source
Net income: -13300000 USD · 2018-01-01 – 2018-03-31 Source
Net income: -41157000 USD · 2018-01-01 – 2018-09-30 Source
Net income: -27108000 USD · 2018-01-01 – 2018-06-30 Source
Net income: -54758000 USD · 2018-01-01 – 2018-12-31 Source
Net income: -41157000 USD · 2018-01-01 – 2018-09-30 Source

Operating cash flow

-51.7 million USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Operating cash flow: -16383000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -27302000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -16383000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -40268000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -27302000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -51666000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -40268000 USD · 2018-01-01 – 2018-09-30 Source

Capital expenditure

390 thousand USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Capital expenditure: 204000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 243000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 204000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 269000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 243000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 390000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 269000 USD · 2018-01-01 – 2018-09-30 Source

Free cash flow

-52.1 million USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Operating cash flow: -16383000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -27302000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -16383000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -40268000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -27302000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -51666000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -40268000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 204000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 243000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 204000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 269000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 243000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 390000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 269000 USD · 2018-01-01 – 2018-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-03-28.

Financial data available through: 2017-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2017-12-31
Operating income: 6 of 11 periods available· newest 2017-12-31
Net income: 6 of 11 periods available· newest 2017-12-31
Operating cash flow: 6 of 11 periods available· newest 2017-12-31
Capital expenditure: 6 of 11 periods available· newest 2017-12-31
Total assets: 5 of 11 periods available· newest 2017-12-31
liabilities: No compatible figures in this window
Current assets: 5 of 11 periods available· newest 2017-12-31
Current liabilities: 5 of 11 periods available· newest 2017-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2017-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-45.7%

Prior period

USD 13.26 million

2016-01-01 – 2016-12-31
Current period

USD 7.2 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

7195000 − 13260000 = -6065000 USD

13260000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
7195000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Year-over-year change in Revenue: -6065000 USD Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 7195000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#245327 Filing: 000143778618000013 Input fundies:Revenue: 13260000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#244619 Filing: 000143778618000013
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 1.67 million

Prior period

−USD 53.53 million

2016-01-01 – 2016-12-31
Current period

−USD 51.86 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-51862000 − -53530000 = 1668000 USD

-53530000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-51862000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Year-over-year change in Net income: 1668000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -51862000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233721 Filing: 000143778619000006 Input fundies:NetIncome: -53530000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233567 Filing: 000143778619000006
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 11.12 million

Prior period

−USD 35.74 million

2016-01-01 – 2016-12-31
Current period

−USD 46.86 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-46859000 − -35740000 = -11119000 USD

-35740000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-46859000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Year-over-year change in Operating cash flow: -11119000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -46859000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233063 Filing: 000143778619000006 Input fundies:OperatingCashFlow: -35740000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#232811 Filing: 000143778619000006
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+221.8%

Prior period

USD 133,000

2016-01-01 – 2016-12-31
Current period

USD 428,000

2017-01-01 – 2017-12-31

Exact inputs and evidence

428000 − 133000 = 295000 USD

133000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
428000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Year-over-year change in Capital expenditure: 295000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 428000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#246504 Filing: 000143778619000006 Input fundies:CapitalExpenditure: 133000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#246295 Filing: 000143778619000006
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 7.2 million 100% of revenue
Cost of revenue USD 84,000 1.2% of revenue
Operating expenses USD 60.01 million 834% of revenue
Other operating costs Derived −USD 84,000 −1.2% of revenue
Operating income −USD 52.81 million −734% of revenue
Tax, interest and other Derived −USD 950,000 −13% of revenue
Net income −USD 51.86 million −721% of revenue

Cash

Operating cash flow −USD 46.86 million −651% of revenue
Capital expenditure USD 428,000 5.9% of revenue
Free cash flow Derived −USD 47.29 million −657% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Operating loss: operating costs were 467% of revenue.
2013 Operating loss: operating costs were 1,042% of revenue.
2014 Operating loss: operating costs were 564% of revenue.
2015 Operating loss: operating costs were 515% of revenue.
2016 Operating loss: operating costs were 509% of revenue.
2017 Operating loss: operating costs were 834% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	2960000	13835000 Derived	-10875000	-35000 Derived	-10840000	-9872000 Derived	Source 2012-01-01 – 2012-12-31: 2960000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -10875000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -10840000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -9578000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 294000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	1599000	16656000 Derived	-15057000	918000 Derived	-15975000	-14473000 Derived	Source 2013-01-01 – 2013-12-31: 1599000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -15057000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -15975000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -14298000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 175000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	6433000	36311000 Derived	-29878000	4273000 Derived	-34151000	-21013000 Derived	Source 2014-01-01 – 2014-12-31: 6433000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -29878000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -34151000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -20669000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 344000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	9510000	48995000 Derived	-39485000	-40000 Derived	-39445000	-38228000 Derived	Source 2015-01-01 – 2015-12-31: 9510000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -39485000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -39445000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -37801000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 427000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	13260000	67474000 Derived	-54214000	-684000 Derived	-53530000	-35873000 Derived	Source 2016-01-01 – 2016-12-31: 13260000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -54214000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -53530000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -35740000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 133000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	7195000	60007000 Derived	-52812000	-950000 Derived	-51862000	-47287000 Derived	Source 2017-01-01 – 2017-12-31: 7195000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -52812000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -51862000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -46859000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 428000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 7.2M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	2960000	Revenue: 2960000 Open source
20132013-12-31	Revenue	1599000	Revenue: 1599000 Open source
20142014-12-31	Revenue	6433000	Revenue: 6433000 Open source
20152015-12-31	Revenue	9510000	Revenue: 9510000 Open source
20162016-12-31	Revenue	13260000	Revenue: 13260000 Open source
20172017-12-31	Revenue	7195000	Revenue: 7195000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-45.7% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	No prior comparable period	Revenue: 2960000 Open source
20132013-12-31	Year over year	-46%	Revenue: 1599000 Open source Revenue: 2960000 Open source
20142014-12-31	Year over year	302.3%	Revenue: 6433000 Open source Revenue: 1599000 Open source
20152015-12-31	Year over year	47.8%	Revenue: 9510000 Open source Revenue: 6433000 Open source
20162016-12-31	Year over year	39.4%	Revenue: 13260000 Open source Revenue: 9510000 Open source
20172017-12-31	Year over year	-45.7%	Revenue: 7195000 Open source Revenue: 13260000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -734% 2017

Net margin -720.8% 2017

Free cash flow margin -657.2% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	-367.4%	Operating Income: -10875000 Open source Revenue: 2960000 Open source
20132013-12-31	Operating margin	-941.7%	Operating Income: -15057000 Open source Revenue: 1599000 Open source
20142014-12-31	Operating margin	-464.4%	Operating Income: -29878000 Open source Revenue: 6433000 Open source
20152015-12-31	Operating margin	-415.2%	Operating Income: -39485000 Open source Revenue: 9510000 Open source
20162016-12-31	Operating margin	-408.9%	Operating Income: -54214000 Open source Revenue: 13260000 Open source
20172017-12-31	Operating margin	-734%	Operating Income: -52812000 Open source Revenue: 7195000 Open source
20122012-12-31	Net margin	-366.2%	Net Income: -10840000 Open source Revenue: 2960000 Open source
20132013-12-31	Net margin	-999.1%	Net Income: -15975000 Open source Revenue: 1599000 Open source
20142014-12-31	Net margin	-530.9%	Net Income: -34151000 Open source Revenue: 6433000 Open source
20152015-12-31	Net margin	-414.8%	Net Income: -39445000 Open source Revenue: 9510000 Open source
20162016-12-31	Net margin	-403.7%	Net Income: -53530000 Open source Revenue: 13260000 Open source
20172017-12-31	Net margin	-720.8%	Net Income: -51862000 Open source Revenue: 7195000 Open source
20122012-12-31	Free cash flow margin	-333.5%	Revenue: 2960000 Open source Operating Cash Flow: -9578000 Open source Capital Expenditure: 294000 Open source
20132013-12-31	Free cash flow margin	-905.1%	Revenue: 1599000 Open source Operating Cash Flow: -14298000 Open source Capital Expenditure: 175000 Open source
20142014-12-31	Free cash flow margin	-326.6%	Revenue: 6433000 Open source Operating Cash Flow: -20669000 Open source Capital Expenditure: 344000 Open source
20152015-12-31	Free cash flow margin	-402%	Revenue: 9510000 Open source Operating Cash Flow: -37801000 Open source Capital Expenditure: 427000 Open source
20162016-12-31	Free cash flow margin	-270.5%	Revenue: 13260000 Open source Operating Cash Flow: -35740000 Open source Capital Expenditure: 133000 Open source
20172017-12-31	Free cash flow margin	-657.2%	Revenue: 7195000 Open source Operating Cash Flow: -46859000 Open source Capital Expenditure: 428000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -46.9M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-9578000	Operating Cash Flow: -9578000 Open source
20132013-12-31	Operating cash flow	-14298000	Operating Cash Flow: -14298000 Open source
20142014-12-31	Operating cash flow	-20669000	Operating Cash Flow: -20669000 Open source
20152015-12-31	Operating cash flow	-37801000	Operating Cash Flow: -37801000 Open source
20162016-12-31	Operating cash flow	-35740000	Operating Cash Flow: -35740000 Open source
20172017-12-31	Operating cash flow	-46859000	Operating Cash Flow: -46859000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -47.3M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	-9872000	Operating Cash Flow: -9578000 Open source Capital Expenditure: 294000 Open source
20132013-12-31	Free cash flow	-14473000	Operating Cash Flow: -14298000 Open source Capital Expenditure: 175000 Open source
20142014-12-31	Free cash flow	-21013000	Operating Cash Flow: -20669000 Open source Capital Expenditure: 344000 Open source
20152015-12-31	Free cash flow	-38228000	Operating Cash Flow: -37801000 Open source Capital Expenditure: 427000 Open source
20162016-12-31	Free cash flow	-35873000	Operating Cash Flow: -35740000 Open source Capital Expenditure: 133000 Open source
20172017-12-31	Free cash flow	-47287000	Operating Cash Flow: -46859000 Open source Capital Expenditure: 428000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Liabilities / assets	Not reported	No source recorded
2013-12-31	Liabilities / assets	Not reported	Total Assets: 30965000 Open source
2014-12-31	Liabilities / assets	Not reported	Total Assets: 78383000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 116145000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 114495000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 153834000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.55× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Current assets / current liabilities	Not reported	No source recorded
20132013-12-31	Current assets / current liabilities	15.53×	Current Assets: 30670000 Open source Current Liabilities: 1975000 Open source
20142014-12-31	Current assets / current liabilities	6.53×	Current Assets: 77982000 Open source Current Liabilities: 11947000 Open source
20152015-12-31	Current assets / current liabilities	16.25×	Current Assets: 115560000 Open source Current Liabilities: 7111000 Open source
20162016-12-31	Current assets / current liabilities	5.92×	Current Assets: 114081000 Open source Current Liabilities: 19263000 Open source
20172017-12-31	Current assets / current liabilities	10.55×	Current Assets: 153143000 Open source Current Liabilities: 14520000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 10.84 million Exact value Exact value: -10840000 USD 2012-01-01 – 2012-12-31: -10840000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immune Design Corp. · 2012-12-31 Immune Design Corp. (edgar:1437786) Net Income: -10840000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10840000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000162828015002175/imdz-20141231.xml#190624 Filing: 000162828015002175 The citation records this snapshot. The page link may show a newer release later.	−USD 9.58 million Exact value Exact value: -9578000 USD 2012-01-01 – 2012-12-31: -9578000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immune Design Corp. · 2012-12-31 Immune Design Corp. (edgar:1437786) Operating Cash Flow: -9578000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9578000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000162828015002175/imdz-20141231.xml#189869 Filing: 000162828015002175 The citation records this snapshot. The page link may show a newer release later.	USD 294,000 Exact value Exact value: 294000 USD 2012-01-01 – 2012-12-31: 294000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immune Design Corp. · 2012-12-31 Immune Design Corp. (edgar:1437786) Capital Expenditure: 294000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 294000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000162828015002175/imdz-20141231.xml#199809 Filing: 000162828015002175 The citation records this snapshot. The page link may show a newer release later.	−USD 9.87 million Calculation and evidence -9578000 − 294000 USD Exact free cash flow: -9872000 USD 2012-01-01 – 2012-12-31: -9578000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 294000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immune Design Corp. · 2012-12-31 Immune Design Corp. (edgar:1437786) Free cash flow: -9872000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9578000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000162828015002175/imdz-20141231.xml#189869 Filing: 000162828015002175 Input fundies:CapitalExpenditure: 294000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000162828015002175/imdz-20141231.xml#199809 Filing: 000162828015002175 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 15.98 million Exact value Exact value: -15975000 USD 2013-01-01 – 2013-12-31: -15975000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immune Design Corp. · 2013-12-31 Immune Design Corp. (edgar:1437786) Net Income: -15975000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15975000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778616000031/imdz-20151231.xml#210301 Filing: 000143778616000031 The citation records this snapshot. The page link may show a newer release later.	−USD 14.3 million Exact value Exact value: -14298000 USD 2013-01-01 – 2013-12-31: -14298000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immune Design Corp. · 2013-12-31 Immune Design Corp. (edgar:1437786) Operating Cash Flow: -14298000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14298000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778616000031/imdz-20151231.xml#209545 Filing: 000143778616000031 The citation records this snapshot. The page link may show a newer release later.	USD 175,000 Exact value Exact value: 175000 USD 2013-01-01 – 2013-12-31: 175000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immune Design Corp. · 2013-12-31 Immune Design Corp. (edgar:1437786) Capital Expenditure: 175000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 175000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778616000031/imdz-20151231.xml#219854 Filing: 000143778616000031 The citation records this snapshot. The page link may show a newer release later.	−USD 14.47 million Calculation and evidence -14298000 − 175000 USD Exact free cash flow: -14473000 USD 2013-01-01 – 2013-12-31: -14298000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 175000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immune Design Corp. · 2013-12-31 Immune Design Corp. (edgar:1437786) Free cash flow: -14473000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14298000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778616000031/imdz-20151231.xml#209545 Filing: 000143778616000031 Input fundies:CapitalExpenditure: 175000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778616000031/imdz-20151231.xml#219854 Filing: 000143778616000031 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 34.15 million Exact value Exact value: -34151000 USD 2014-01-01 – 2014-12-31: -34151000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immune Design Corp. · 2014-12-31 Immune Design Corp. (edgar:1437786) Net Income: -34151000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34151000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778617000014/imdz-20161231.xml#214131 Filing: 000143778617000014 The citation records this snapshot. The page link may show a newer release later.	−USD 20.67 million Exact value Exact value: -20669000 USD 2014-01-01 – 2014-12-31: -20669000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immune Design Corp. · 2014-12-31 Immune Design Corp. (edgar:1437786) Operating Cash Flow: -20669000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20669000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778617000014/imdz-20161231.xml#213375 Filing: 000143778617000014 The citation records this snapshot. The page link may show a newer release later.	USD 344,000 Exact value Exact value: 344000 USD 2014-01-01 – 2014-12-31: 344000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immune Design Corp. · 2014-12-31 Immune Design Corp. (edgar:1437786) Capital Expenditure: 344000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 344000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778617000014/imdz-20161231.xml#226153 Filing: 000143778617000014 The citation records this snapshot. The page link may show a newer release later.	−USD 21.01 million Calculation and evidence -20669000 − 344000 USD Exact free cash flow: -21013000 USD 2014-01-01 – 2014-12-31: -20669000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 344000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immune Design Corp. · 2014-12-31 Immune Design Corp. (edgar:1437786) Free cash flow: -21013000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20669000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778617000014/imdz-20161231.xml#213375 Filing: 000143778617000014 Input fundies:CapitalExpenditure: 344000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778617000014/imdz-20161231.xml#226153 Filing: 000143778617000014 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 39.45 million Exact value Exact value: -39445000 USD 2015-01-01 – 2015-12-31: -39445000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immune Design Corp. · 2015-12-31 Immune Design Corp. (edgar:1437786) Net Income: -39445000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39445000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#212124 Filing: 000143778618000013 The citation records this snapshot. The page link may show a newer release later.	−USD 37.8 million Exact value Exact value: -37801000 USD 2015-01-01 – 2015-12-31: -37801000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immune Design Corp. · 2015-12-31 Immune Design Corp. (edgar:1437786) Operating Cash Flow: -37801000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37801000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#211368 Filing: 000143778618000013 The citation records this snapshot. The page link may show a newer release later.	USD 427,000 Exact value Exact value: 427000 USD 2015-01-01 – 2015-12-31: 427000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immune Design Corp. · 2015-12-31 Immune Design Corp. (edgar:1437786) Capital Expenditure: 427000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 427000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#225461 Filing: 000143778618000013 The citation records this snapshot. The page link may show a newer release later.	−USD 38.23 million Calculation and evidence -37801000 − 427000 USD Exact free cash flow: -38228000 USD 2015-01-01 – 2015-12-31: -37801000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 427000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immune Design Corp. · 2015-12-31 Immune Design Corp. (edgar:1437786) Free cash flow: -38228000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37801000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#211368 Filing: 000143778618000013 Input fundies:CapitalExpenditure: 427000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778618000013/imdz-20171231.xml#225461 Filing: 000143778618000013 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 53.53 million Exact value Exact value: -53530000 USD 2016-01-01 – 2016-12-31: -53530000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immune Design Corp. · 2016-12-31 Immune Design Corp. (edgar:1437786) Net Income: -53530000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53530000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233567 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.	−USD 35.74 million Exact value Exact value: -35740000 USD 2016-01-01 – 2016-12-31: -35740000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immune Design Corp. · 2016-12-31 Immune Design Corp. (edgar:1437786) Operating Cash Flow: -35740000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35740000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#232811 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.	USD 133,000 Exact value Exact value: 133000 USD 2016-01-01 – 2016-12-31: 133000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immune Design Corp. · 2016-12-31 Immune Design Corp. (edgar:1437786) Capital Expenditure: 133000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 133000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#246295 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.	−USD 35.87 million Calculation and evidence -35740000 − 133000 USD Exact free cash flow: -35873000 USD 2016-01-01 – 2016-12-31: -35740000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 133000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immune Design Corp. · 2016-12-31 Immune Design Corp. (edgar:1437786) Free cash flow: -35873000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35740000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#232811 Filing: 000143778619000006 Input fundies:CapitalExpenditure: 133000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#246295 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 51.86 million Exact value Exact value: -51862000 USD 2017-01-01 – 2017-12-31: -51862000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Net Income: -51862000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51862000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233721 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.	−USD 46.86 million Exact value Exact value: -46859000 USD 2017-01-01 – 2017-12-31: -46859000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Operating Cash Flow: -46859000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46859000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233063 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.	USD 428,000 Exact value Exact value: 428000 USD 2017-01-01 – 2017-12-31: 428000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Capital Expenditure: 428000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 428000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#246504 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.	−USD 47.29 million Calculation and evidence -46859000 − 428000 USD Exact free cash flow: -47287000 USD 2017-01-01 – 2017-12-31: -46859000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 428000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immune Design Corp. · 2017-12-31 Immune Design Corp. (edgar:1437786) Free cash flow: -47287000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:08:57Z Snapshot: fd5f8f43031e4cbd700f4957a8b7fe26c364620e4db65fe7b0dda9566f8b3a32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1437786?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -46859000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#233063 Filing: 000143778619000006 Input fundies:CapitalExpenditure: 428000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1437786/000143778619000006/imdz-20181231.xml#246504 Filing: 000143778619000006 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

51 filings · 1,253 latest values · 1,253 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001437786, 1437786, IMDZ, edgar:1437786

Also known as IMMUNE DESIGN CORP., Immune Design Corp., VACCSYS INC

Immune Design Corp.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation